Alumis Presents Positive Data From Phase 2 Clinical Trial Of

Alumis Presents Positive Data From Phase 2 Clinical Trial Of ESK-001, An Oral Allosteric TYK2 Inhibitor For The Treatment Of Plaque Psoriasis, At AAD ...

Alumis Presents Positive Data From Phase 2 Clinical Trial Of ESK-001, An Oral Allosteric TYK2 Inhibitor For The Treatment Of Plaque Psoriasis, At AAD ...

menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , San Diego , California , American , Kim Papp , Martin Babler , American Academy Of Dermatology , Alumis Inc , Nasdaq , Probity Medical Research , American Academy , Annual Meeting , Psoriasis Area , Severity Score , Alumi Chief Medical Officer , Chief Executive Officer ,